A new approach to immunotherapy has shown long-term survival rates exceeding 50% in children with high-risk neuroblastoma. Stem cell transplantation from a parent provides a renewed immune system that responds better to immunotherapies, improving outcomes.
Researchers found that cancer cells prevent surrounding cells from fighting tumors, but medication can reverse this process. Metastatic tumor cells retain cellular plasticity and change gene expression based on the neuroblastoma genetic subtype.
Researchers identified a rare genetic defect in the DOCK11 gene causing abnormalities in white and red blood cells, leading to inflammation and immune system dysregulation. The defect also affects T cell activation, with potential connections to tumor diseases.
Eleni Tomazou's project aims to create in vitro and in vivo models of pediatric sarcomas to accelerate drug discovery and precision medicine. Her work could lead to a significant impact on the treatment of these deadly cancers.
Schwann cells in nerve healing take over immune cell functions to prevent excessive tissue damage and promote regeneration. Similarly, they may stop chronic inflammation in childhood nerve tumors, making them benign. Schwann cells can also regulate T-cell activity, potentially curbing cancer growth.
A recent study published in Frontiers in Pediatrics suggests that modern immunotherapies, such as CAR-T cell therapy, could replace traditional stem cell transplantation for high-risk ALL patients. The review also discusses the importance of reducing long-term side effects, including organ damage and secondary cancers.
An international research team discovered a new rare disease caused by a disrupted Helios-dependent epigenetic regulation mechanism, leading to T and B cell defects. The study highlights the importance of Helios in immune homeostasis and suggests potential therapeutic targets for immunodeficiency and malignancy.
A new study establishes a more tolerable chemotherapy regimen for children with high-risk neuroblastoma, while maintaining its effectiveness. The European Neuroblastoma Study Group's rCOJEC regimen showed significant reductions in side effects compared to the US-based MSKCC-N5 regimen.
A new study uses liquid biopsy analysis to detect and classify childhood tumors based on their unique epigenetic signatures. This approach enables minimally invasive diagnosis and monitoring without the need for tumor biopsies, holding promise for improved treatment outcomes and personalized therapies.
Scientists have discovered a natural signal molecule that stops the uncontrolled growth of malignant tumors and promotes the healing of injured nerve fibers. The molecule, EGFL8, is produced by Schwann cells in benign neuroblastomas and stimulates tumor cell maturation, leading to better survival rates for patients.
Researchers have discovered that cancer cells use their nucleus to sense environmental compression and trigger responses to evade overcrowded areas. The study proposes a new mechanism by which tumor cells cope with the lack of space and compressive stresses, involving the unfolded and stretched nuclear membranes.